New Current Report Filed with the SEC Disclosing Receipt of a Notice of Delisting, the Failure to Satisfy a Continued Listing Rule or Standard or the Transfer of a Listing: 8-K12B/A – AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)

A current report on Form 8-K was just filed with the U.S. Securities & Exchange Commission (SEC) disclosing receipt of a notice of delisting, the failure to satisfy a continued listing rule or standard or the transfer of a listing. Details of the current report are:

8-K12B/A – AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
Filed: 2017-01-06 AccNo: 0001144204-17-000976 Size: 367 KB

Item 1.01: Entry into a Material Definitive Agreement

Item 2.01: Completion of Acquisition or Disposition of Assets

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.02: Unregistered Sales of Equity Securities

Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 8.01: Other Events

Item 9.01: Financial Statements and Exhibits
Filing Date: 2017-01-06T11:10:08-05:00

This is a breaking news story. You can access the complete current report through the SEC’s Edgar system: http://www.sec.gov/Archives/edgar/data/1012477/000114420417000976/0001144204-17-000976-index.htm